Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AVIR

Atea Pharmaceuticals Inc

Mar 10 • 04:00PM ET

6.05

-0.10 -1.63 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA GILD BNTX JNJ NVAX VXRT RIGL PTGX CYCN

| Held by: VTI IWM IWN VXF IBB SCHA DFAS VTWO IWC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.95	Insider Own	21.22%	Shs Outstand	78.13M	Perf Week	25.52%
Market Cap	482.02M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	0.00%	Shs Float	62.77M	Perf Month	45.78%
Enterprise Value	181.03M	PEG	-	EPS next Q	-0.56	Inst Own	68.64%	Short Float	12.30%	Perf Quarter	90.85%
Income	-158.35M	P/S	-	EPS this Y	0.52%	Inst Trans	6.31%	Short Ratio	15.13	Perf Half Y	86.15%
Sales	0.00M	P/B	1.72	EPS next Y	28.24%	ROA	-40.61%	Short Interest	7.72M	Perf YTD	69.47%
Book/sh	3.53	P/C	1.60	EPS next 5Y	20.90%	ROE	-44.34%	52W High	6.18 -2.10%	Perf Year	107.19%
Cash/sh	3.79	P/FCF	-	EPS past 3/5Y	-11.75% -71.02%	ROIC	-57.49%	52W Low	2.45 146.44%	Perf 3Y	81.14%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.60% 5.92%	Perf 5Y	-90.56%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	2.37%	Oper. Margin	-	ATR (14)	0.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.82	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	82.17	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	7.82	EPS Q/Q	-44.62%	SMA20	24.58%	Beta	0.19	Target Price	8.83
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	44.58%	Rel Volume	2.11	Prev Close	6.15
Employees	55	LT Debt/Eq	0.00	Earnings	Mar 05 AMC	SMA200	72.90%	Avg Volume	510.16K	Price	6.05
IPO	Oct 30, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.53% -	Trades		Volume	1,075,811	Change	-1.63%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-24	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$2 → $6.88
Aug-10-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$14 → $7
Nov-18-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-20-21	Downgrade	JP Morgan	Overweight → Neutral	$61 → $16
Oct-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$55
Nov-25-20	Initiated	Evercore ISI	Outperform
Nov-24-20	Initiated	William Blair	Outperform	$60
Nov-24-20	Initiated	Morgan Stanley	Overweight	$49
Nov-24-20	Initiated	JP Morgan	Overweight	$45

Mar-06-26 08:30AM	Atea Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby) +11.13%
12:02AM	Atea Pharmaceuticals Inc (AVIR) Q4 2025 Earnings Call Highlights: Advancing HCV Treatments and ... (GuruFocus.com)
Mar-05-26 06:47PM	Atea Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) +6.43%
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-26-26 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 (GlobeNewswire)
07:00AM	Loading…
Feb-24-26 07:00AM	Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026 (GlobeNewswire)
Jan-19-26 11:19AM	JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens (Pharmaceutical Technology)
Jan-15-26 02:32PM	Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference (MarketBeat)
Jan-09-26 07:17AM	Atea Pharmaceuticals to highlight strategic priorities for FY26 (TipRanks)
Jan-08-26 07:00AM	Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-26 07:00AM	Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-25 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
Dec-02-25 04:46PM	ReAlta Life Sciences Designates Dr. Howard Berman as Executive Chairman (Exec Edge)
Nov-19-25 08:02PM	Atea Pharmaceuticals Inc (AVIR) Q3 2025 Earnings Call Highlights: Strategic Advances in HCV ... (GuruFocus.com)
07:00AM	Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
Nov-12-25 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -12.57%
Nov-07-25 08:00AM	Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 (GlobeNewswire)
Nov-05-25 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025 (GlobeNewswire)
Oct-22-25 07:00AM	Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting 2025 (GlobeNewswire)
Sep-02-25 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-07-25 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 (GlobeNewswire)
Jun-24-25 07:00AM	Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America (GlobeNewswire)
May-12-25 04:11PM	Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.82% -11.15%
May-07-25 07:00AM	Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 (GlobeNewswire)
May-01-25 07:00AM	Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 (GlobeNewswire)
Apr-23-25 07:00AM	Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 (GlobeNewswire)
Apr-17-25 07:00AM	Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program (GlobeNewswire)
Apr-09-25 07:00AM	Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (GlobeNewswire)
01:58PM	Loading…
Mar-26-25 01:58PM	Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value (GlobeNewswire)
08:00AM	The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors (Business Wire)
Mar-21-25 05:54PM	Atea Pharmaceuticals Issues Statement Regarding Director Nominations (GlobeNewswire)
08:25AM	Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory (InsiderMonkey)
Mar-19-25 07:00AM	Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025 (GlobeNewswire)
Mar-07-25 12:46PM	Q4 2024 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:17AM	Atea Pharmaceuticals Inc (AVIR) Q4 2024 Earnings Call Highlights: Strategic Moves and Promising ... (GuruFocus.com)
Mar-06-25 04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-25 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors (GlobeNewswire)
Jan-13-25 07:00AM	Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 07:00AM	Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 05:05PM	Concerned Shareholder Group Calls for Atea Pharmaceuticals to Appoint a New, Shareholder-Oriented Lead Independent Director to Oversee Strategic Review Process (Business Wire)
Dec-16-24 05:00AM	Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships (GlobeNewswire) +5.80%
Dec-05-24 07:06AM	Atea Pharmaceuticals announces results from Phase 2 regimen of bemnifosbuvir (TipRanks) -5.94%
Dec-04-24 03:14PM	After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study (Benzinga) -10.49%
07:00AM	Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV) (GlobeNewswire)
06:09AM	Atea plans Phase 3 study for hepatitis C drug after mid-stage results (BioPharma Dive)
Nov-26-24 07:00AM	Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-22-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-15-24 11:00AM	Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Nov-11-24 08:01PM	Atea Pharmaceuticals Inc (AVIR) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com)
Nov-07-24 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (GlobeNewswire)
Oct-30-24 07:00AM	Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 (GlobeNewswire)
Oct-16-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks) +6.20%
Oct-09-24 05:19PM	Atea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Oct-04-24 09:35AM	Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-30-24 09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-13-24 02:53PM	Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus (Benzinga) +5.45%
07:00AM	Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 (GlobeNewswire)
Aug-28-24 09:40AM	Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? (Zacks)
07:00AM	Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway (GlobeNewswire)
Aug-12-24 12:00PM	All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy (Zacks)
09:40AM	Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-07-24 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +7.03%
Jul-31-24 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.04%
May-29-24 07:00AM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-22-24 07:00AM	Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 (GlobeNewswire) +5.82%
May-15-24 09:01AM	Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com) -6.31%
May-14-24 04:05PM	Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-07-24 07:00AM	Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024 (GlobeNewswire)
Apr-29-24 07:00AM	Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 (GlobeNewswire)
Mar-27-24 07:00AM	Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients (GlobeNewswire) +6.10%
Feb-29-24 10:03AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:58PM	Atea Pharmaceuticals Inc (AVIR) Announces Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-21-24 07:00AM	Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 (GlobeNewswire)
Jan-10-24 09:30AM	Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study (Zacks)
Jan-08-24 04:05PM	Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19 (GlobeNewswire) +11.29%
Jan-03-24 07:00AM	Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-13-23 07:00AM	Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 03:57PM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript (Insider Monkey) -9.12%
05:48AM	Q3 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 04:05PM	Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Nov-02-23 07:00AM	Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-01-23 07:00AM	Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 (GlobeNewswire) -5.23%
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Sep-06-23 07:00AM	Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-09-23 06:58AM	Q2 2023 Atea Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 04:05PM	Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 07:00AM	Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 (GlobeNewswire)
Jun-15-23 07:00AM	Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination (GlobeNewswire)
Jun-05-23 04:20PM	Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 07:00AM	Atea Pharmaceuticals Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners Affiliate, Concentra Biosciences (GlobeNewswire) -11.97%
May-26-23 07:02PM	Lordstown Motors and Atea Pharmaceuticals Stock See Action From Activist Investors (Barrons.com)
May-23-23 04:05PM	Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners Affiliate, Concentra Biosciences (GlobeNewswire)
May-10-23 11:53AM	Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2023 Earnings Call Transcript (Insider Monkey)

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sommadossi Jean-Pierre	President, CEO, and Chairman	Feb 03 '26	Option Exercise	1.24	300,000	372,000	767,830	Feb 03 07:46 PM
Murphy Polly A.	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	86,045	Jun 24 06:05 PM
BERGER FRANKLIN M	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	506,497	Jun 24 06:05 PM
Duncan Barbara Gayle	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	62,750	Jun 24 06:05 PM
Polsky Bruce	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	95,206	Jun 24 06:05 PM
Adams Jerome M.	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	62,750	Jun 24 06:05 PM
Lucidi Bruno	Director	Jun 20 '25	Option Exercise	0.00	29,600	0	112,750	Jun 24 06:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVIR

Atea Pharmaceuticals Inc

Upgrade your FINVIZ experience